GlassScriptPhysician profile
Chirag C Patel
NPI 1124224936
$2,650.78
in general payments reported to CMS, 2019-2025
15 companies · $585 in 2025
The $585 reported for 2025 was more than what a typical Retina Specialist provider received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $299 · 2020: $67.21 · 2021: $43.83 · 2022: $324 · 2023: $526 · 2024: $806 · 2025: $585.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,916.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,916.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $751.72 | 2022-2025 | Eylea Hd, Eylea |
| Genentech USA, INC. | $592.26 | 2022-2025 | Vabysmo |
| Astellas Pharma US INC | $207.87 | 2023-2025 | Izervay |
| Apellis Pharmaceuticals, INC. | $189.36 | 2023-2025 | Syfovre |
| Dutch Ophthalmic, USA | $177.08 | 2019 | |
| Alcon Vision LLC | $170.18 | 2019-2023 | Hydrus Microstent |
| Abbvie INC. | $160.98 | 2022-2025 | |
| Alimera Sciences, INC. | $158.36 | 2019-2024 | Iluvien, Yutiq |
| Bausch & Lomb Americas INC. | $64.38 | 2022-2025 | Xipere, Retisert, Visudyne |
| Allergan, INC. | $55.03 | 2019-2021 | |
| Ani Pharmaceuticals, INC. | $50.83 | 2025 | Iluvien, Purified Cortrophin Gel |
| Novartis Pharmaceuticals Corporation | $20.78 | 2019 | |
| Eyepoint US, INC. | $20.74 | 2022 | |
| Janssen Pharmaceuticals, INC | $17.91 | 2024 | Xarelto |
| Spark Therapeutics, INC. | $13.30 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chirag Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.